News & Blogs

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

Talisman needle-free CGM demonstrates strong correlation to blood glucose in clinical studies and moves towards large volume manufacturing

GlucoModicum continues progress towards commercialisation of needle free continuous glucose monitor

GlucoModicum publishes first-in-human data assessing the safety and effectiveness of its MHD technology for accurate needle-free glucose monitoring

GlucoModicum Appoints Peter Gerhardsson to its Board of Directors

GlucoModicum publishes data showing integration of MHD technology with ultra-sensitive biosensor enables accurate needle-free glucose monitoring

GlucoModicum and Phillips-Medisize sign a design and development program for the rapid scale-up of its needle-free continuous glucose monitor

GlucoModicum announces the appointment of Peter Gerhardsson as a Senior Advisor

GlucoModicum’s non-invasive glucose monitoring technology performs 13x better than previous needle free approaches

Enhanced and miniaturized electronics & functionality for the industrial product (“Flint 2”) has been completed

GlucoModicum core patent has been granted in 18 new countries in EU and Asia

GlucoModicum has completed one of the key milestones, M1, in reaching the CE mark for the first in-market product (“Flint 2”)

GlucoModicum has received a Seal of Excellence from the European Commission

GlucoModicum team is growing. We are a team of 20 professionals as of today.

GlucoModicum has created manufacturing capability for increased volumes

GlucoModicum initiates clinical pilot study with Type2 diabetics, using the industrial prototype (“Flint 1”)

Business Finland allocates significant funding to GlucoModicum

Medical Doctor -magazine (Lääkärilehti) covered GlucoModicum in their latest issue

GlucoModicum completes successful pilot clinical trials

GlucoModicum completes industrial grade prototype and sensor

GlucoModicum Clinical Trial raises a lot of interest

GlucoModicum closes the next funding round

Valvira approves Pilot Clinical Trials to evaluate GlucoModicum’s needle-free glucose monitor on Type 2 Diabetics in Finland

GlucoModicum selected as one of the top 40 early-stage health tech companies in Europe

GlucoModicum has closed +1,2MEUR Seed Round

GlucoModicum closes Pre-Seed funding round

GlucoModicum Ltd is established.

GlucoModicum – Health Design 2017 Winner.